tetano
Editor, Senior Moderator
Sci Rep. 2016 Oct 14;6:35173. doi: 10.1038/srep35173.
[h=1]In vivo dendritic cell targeting cellular vaccine induces CD4+ Tfh cell-dependent antibody against influenza virus.[/h] Yamasaki S[SUP]1[/SUP], Shimizu K[SUP]1[/SUP], Kometani K[SUP]2[/SUP], Sakurai M[SUP]1[/SUP], Kawamura M[SUP]1[/SUP], Fujii SI[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] An induction of long-term cellular and humoral immunity is for the goal of vaccines, but the combination of antigens and adjuvant remain unclear. Here, we show, using a cellular vaccine carrying foreign protein antigen plus iNKT cell glycolipid antigen, designated as artificial adjuvant vector cells (aAVCs), that mature XCR1[SUP]-[/SUP] DCs in situ elicit not only ordinal antigen-specific CD4[SUP]+[/SUP]T cells, but also CD4[SUP]+[/SUP] Tfh and germinal center, resulted in inducing long-term antibody production. As a mechanism for leading the long-term antibody production by aAVC, memory CD4[SUP]+[/SUP] Tfh cells but not iNKTfh cells played an important role in a Bcl6 dependent manner. To develop it for influenza infection, we established influenza hemagglutinin-carrying aAVC (aAVC-HA) and found that all the mice vaccinated with aAVC-HA were protected from life-threatening influenza infection. Thus, the in vivo DC targeting therapy by aAVC would be useful for protection against viral infection.
PMID: 27739478 DOI: 10.1038/srep35173
[PubMed - in process] Free full text
[h=1]In vivo dendritic cell targeting cellular vaccine induces CD4+ Tfh cell-dependent antibody against influenza virus.[/h] Yamasaki S[SUP]1[/SUP], Shimizu K[SUP]1[/SUP], Kometani K[SUP]2[/SUP], Sakurai M[SUP]1[/SUP], Kawamura M[SUP]1[/SUP], Fujii SI[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] An induction of long-term cellular and humoral immunity is for the goal of vaccines, but the combination of antigens and adjuvant remain unclear. Here, we show, using a cellular vaccine carrying foreign protein antigen plus iNKT cell glycolipid antigen, designated as artificial adjuvant vector cells (aAVCs), that mature XCR1[SUP]-[/SUP] DCs in situ elicit not only ordinal antigen-specific CD4[SUP]+[/SUP]T cells, but also CD4[SUP]+[/SUP] Tfh and germinal center, resulted in inducing long-term antibody production. As a mechanism for leading the long-term antibody production by aAVC, memory CD4[SUP]+[/SUP] Tfh cells but not iNKTfh cells played an important role in a Bcl6 dependent manner. To develop it for influenza infection, we established influenza hemagglutinin-carrying aAVC (aAVC-HA) and found that all the mice vaccinated with aAVC-HA were protected from life-threatening influenza infection. Thus, the in vivo DC targeting therapy by aAVC would be useful for protection against viral infection.
PMID: 27739478 DOI: 10.1038/srep35173
[PubMed - in process] Free full text